<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TIZANIDINE HYDROCHLORIDE</span><br/>(ti-zan'i-deen)<br/><span class="topboxtradename">Zanaflex<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">skeletal muscle relaxant, central-acting</span><br/><b>Prototype: </b>Cyclobenzaprine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>4 mg tablets; 2 mg, 4 mg, 6 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Centrally-acting alpha-adrenergic agonist that reduces spasticity by increasing presynaptic inhibition of motor neurons. No
         effect on skeletal muscle fibers, the neuromuscular junction, or monosynaptic spinal reflexes. Greatest effect on polysynaptic
         afferent reflex activity at the spinal cord level.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Site of action is the spinal cord; reduces skeletal muscle spasm. Effectiveness indicated by decreased muscle tone.</p>
<h1><a name="uses">Uses</a></h1>
<p>Acute and intermittent management of increased muscle tone associated with spasticity.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tizanidine; lactation. Safety in labor and delivery is unknown.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with hepatic impairment, renal insufficiency (Cl<sub>cr</sub>
</p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Spasticity</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 4 mg and gradually increase to 8 mg q68h prn (max: 3 doses or 36 mg/24 h)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Make dose increments gradually in 2- to 4-mg steps.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Asthenia (tiredness),</span> flu-like syndrome, fever, myasthenia, back pain, infection. <span class="typehead">CNS:</span> <span class="speceff-common">Somnolence, dizziness,</span> dyskinesia, nervousness, depression, anxiety, paresthesia. <span class="typehead">CV:</span> <span class="speceff-common">Hypotension, bradycardia</span>. <span class="typehead">GI:</span> <span class="speceff-common">Dry mouth,</span> constipation, abnormal liver function tests, vomiting, abdominal pain, diarrhea, dyspepsia. <span class="typehead">Respiratory:</span> Pharyngitis, rhinitis. <span class="typehead">Skin:</span> Rash, sweating, skin ulcer. <span class="typehead">Urogenital:</span> <span class="speceff-common">UTI,</span> urinary frequency. <span class="typehead">Special Senses:</span> Speech disorder, blurred vision. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">oral contraceptives</span> decrease clearance of <b>tizanidine.</b> <b>Alcohol</b> will increase peak levels and decrease clearance of tizanidine. Increases levels and toxicity of <b>fluvoxamine,</b> <b>amiodarone,</b> <b>ketoconazole,</b> <b>norfloxacin,</b> <b>ciprofloxacin,</b> and <b>ofloxacin.</b> <span class="typehead">Herbal:</span> <b>Kava-kava,</b> <b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; 40% bioavailability. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Duration:</span> 36 h. <span class="typehead">Distribution:</span> Crosses placenta, distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in the liver. <span class="typehead">Elimination:</span> 60% excreted in urine, 20% in feces. <span class="typehead">Half-Life:</span> 2.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor liver function tests (AST, ALT) during the first 6 mo of treatment (baseline, 1, 3, and 6 mo) and periodically
            thereafter.
         </li>
<li>Monitor cardiovascular status and report orthostatic hypotension or bradycardia.</li>
<li>Monitor closely older adults, those with renal impairment, and women taking oral contraceptives for adverse effects because
            drug clearance is reduced.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Exercise caution with potentially hazardous activities requiring alertness since sedation is a common adverse effect. Effects
            are additive with alcohol or other CNS depressants.
         </li>
<li>Make position changes slowly because of the risk of orthostatic hypotension.</li>
<li>Report unusual sensory experiences; hallucinations and delusions have occurred with tizanidine use.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>